---
authors:
- ReactomeTeam
description: MET is a receptor tyrosine kinase (RTK) (Cooper et al. 1984, Park et
  al. 1984) activated by binding to its ligand, Hepatocyte growth factor/Scatter factor
  (HGF/SF) (Bottaro et al. 1991, Naldini et al. 1991). Similar to other related RTKs,
  such as EGFR, ligand binding induces MET dimerization and trans-autophosphorylation,
  resulting in the active MET receptor complex (Ferracini et al. 1991, Longati et
  al. 1994, Rodrigues and Park 1994, Kirchhofer et al. 2004, Stamos et al. 2004, Hays
  and Watowich 2004). Phosphorylated tyrosines in the cytoplasmic tail of MET serve
  as docking sites for binding of adapter proteins, such as GRB2, SHC1 and GAB1, which
  trigger signal transduction cascades that activate PI3K/AKT, RAS, STAT3, PTK2, RAC1
  and RAP1 signaling (Ponzetto et al. 1994, Pelicci et al. 1995, Weidner et al. 1995,
  Besser et al. 1997, Shen and Novak 1997, Beviglia and Kramer 1999, Rodrigues et
  al. 2000, Sakkab et al. 2000, Schaeper et al. 2000, Lamorte et al. 2002, Wang et
  al. 2002, Chen and Chen 2006, Palamidessi et al. 2008, Chen et al. 2011, Murray
  et al. 2014).<br>Activation of PLC gamma 1 (PLCG1) signaling by MET remains unclear.
  It has been reported that PLCG1 can bind to MET directly (Ponzetto et al. 1994)
  or be recruited by phosphorylated GAB1 (Gual et al. 2000). Tyrosine residue Y307
  of GAB1 that serves as docking sites for PLCG1 may be phosphorylated either by activated
  MET (Watanabe et al. 2006) or SRC (Chan et al. 2010). Another PCLG1 docking site
  on GAB1, tyrosine residue Y373, was reported as the SRC target, while the kinase
  for the main PLCG1 docking site, Y407 of GAB1, is not known (Chan et al. 2010).<br>Signaling
  by MET promotes cell growth, cell survival and motility, which are essential for
  embryonic development (Weidner et al. 1993, Schmidt et al. 1995, Uehara et al. 1995,
  Bladt et al. 1995, Maina et al. 1997, Maina et al. 2001, Helmbacher et al. 2003)
  and tissue regeneration (Huh et al. 2004, Borowiak et al. 2004, Liu 2004, Chmielowiec
  et al. 2007). MET signaling is frequently aberrantly activated in cancer, through
  MET overexpression or activating MET mutations (Schmidt et al. 1997, Pennacchietti
  et al. 2003, Smolen et al. 2006, Bertotti et al. 2009).<br>Considerable progress
  has recently been made in the development of HGF-MET inhibitors in cancer therapy.
  These include inhibitors of HGF activators, HGF inhibitors and MET antagonists,
  which are protein therapeutics that act outside the cell. Kinase inhibitors function
  inside the cell and have constituted the largest effort towards MET-based therapeutics
  (Gherardi et al. 2012).<br>Pathogenic bacteria of the species Listeria monocytogenes,
  exploit MET receptor as an entryway to host cells (Shen et al. 2000, Veiga and Cossart
  2005, Neimann et al. 2007).<br>For review of MET signaling, please refer to Birchmeier
  et al. 2003, Trusolino et al. 2010, Gherardi et al. 2012, Petrini 2015.  View original
  pathway at [http://www.reactome.org/PathwayBrowser/#DIAGRAM=6806834 Reactome].
last-edited: 2021-01-25
organisms:
- Homo sapiens
redirect_from:
- /index.php/Pathway:WP4120
- /instance/WP4120
schema-jsonld:
- '@context': https://schema.org/
  '@id': https://wikipathways.github.io/pathways/WP4120.html
  '@type': Dataset
  creator:
    '@type': Organization
    name: WikiPathways
  description: MET is a receptor tyrosine kinase (RTK) (Cooper et al. 1984, Park et
    al. 1984) activated by binding to its ligand, Hepatocyte growth factor/Scatter
    factor (HGF/SF) (Bottaro et al. 1991, Naldini et al. 1991). Similar to other related
    RTKs, such as EGFR, ligand binding induces MET dimerization and trans-autophosphorylation,
    resulting in the active MET receptor complex (Ferracini et al. 1991, Longati et
    al. 1994, Rodrigues and Park 1994, Kirchhofer et al. 2004, Stamos et al. 2004,
    Hays and Watowich 2004). Phosphorylated tyrosines in the cytoplasmic tail of MET
    serve as docking sites for binding of adapter proteins, such as GRB2, SHC1 and
    GAB1, which trigger signal transduction cascades that activate PI3K/AKT, RAS,
    STAT3, PTK2, RAC1 and RAP1 signaling (Ponzetto et al. 1994, Pelicci et al. 1995,
    Weidner et al. 1995, Besser et al. 1997, Shen and Novak 1997, Beviglia and Kramer
    1999, Rodrigues et al. 2000, Sakkab et al. 2000, Schaeper et al. 2000, Lamorte
    et al. 2002, Wang et al. 2002, Chen and Chen 2006, Palamidessi et al. 2008, Chen
    et al. 2011, Murray et al. 2014).<br>Activation of PLC gamma 1 (PLCG1) signaling
    by MET remains unclear. It has been reported that PLCG1 can bind to MET directly
    (Ponzetto et al. 1994) or be recruited by phosphorylated GAB1 (Gual et al. 2000).
    Tyrosine residue Y307 of GAB1 that serves as docking sites for PLCG1 may be phosphorylated
    either by activated MET (Watanabe et al. 2006) or SRC (Chan et al. 2010). Another
    PCLG1 docking site on GAB1, tyrosine residue Y373, was reported as the SRC target,
    while the kinase for the main PLCG1 docking site, Y407 of GAB1, is not known (Chan
    et al. 2010).<br>Signaling by MET promotes cell growth, cell survival and motility,
    which are essential for embryonic development (Weidner et al. 1993, Schmidt et
    al. 1995, Uehara et al. 1995, Bladt et al. 1995, Maina et al. 1997, Maina et al.
    2001, Helmbacher et al. 2003) and tissue regeneration (Huh et al. 2004, Borowiak
    et al. 2004, Liu 2004, Chmielowiec et al. 2007). MET signaling is frequently aberrantly
    activated in cancer, through MET overexpression or activating MET mutations (Schmidt
    et al. 1997, Pennacchietti et al. 2003, Smolen et al. 2006, Bertotti et al. 2009).<br>Considerable
    progress has recently been made in the development of HGF-MET inhibitors in cancer
    therapy. These include inhibitors of HGF activators, HGF inhibitors and MET antagonists,
    which are protein therapeutics that act outside the cell. Kinase inhibitors function
    inside the cell and have constituted the largest effort towards MET-based therapeutics
    (Gherardi et al. 2012).<br>Pathogenic bacteria of the species Listeria monocytogenes,
    exploit MET receptor as an entryway to host cells (Shen et al. 2000, Veiga and
    Cossart 2005, Neimann et al. 2007).<br>For review of MET signaling, please refer
    to Birchmeier et al. 2003, Trusolino et al. 2010, Gherardi et al. 2012, Petrini
    2015.  View original pathway at [http://www.reactome.org/PathwayBrowser/#DIAGRAM=6806834
    Reactome].
  keywords:
  - 'p-Y1234,Y1235,Y1356-MET '
  - pro-HGF
  - 'MyrG-p-Y419-SRC '
  - 'STAM '
  - 'HGFAC(408-655) '
  - 'MET '
  - 'p-Y1003,4Y-MET '
  - 'PTPN1 '
  - SOS1
  - 'CBL '
  - dimer:SHC1-2
  - 'p-Y1234,Y1235,Y1349,Y1356-MET '
  - GTP
  - HGF:p-4Y-MET:p-5Y-GAB1, HGF:p-4Y-MET:GRB2-1:p-5Y-GAB1
  - 'MUC20 '
  - dimer:p-Y194,Y397,Y576,Y577-PTK2:MyrG-p-Y419-SRC
  - 'UBC(1-76) '
  - 'TNS3 '
  - dimer:STAT3
  - 'PTPN2 '
  - 'UBC(381-456) '
  - MyrG-p-Y419-SRC
  - cascade
  - 'CRK '
  - TNS4:ITGB1
  - 'UBB(77-152) '
  - p21 RAS:GTP
  - ARF6:GTP
  - 'UBA52(1-76) '
  - ligase
  - HGF:p-4Y-MET:p-5Y-GAB1, HGF:p-4Y-MET:GRB2-1:p-5Y-GAB1:PI3K
  - 'SHC1-2 '
  - 'HGS '
  - HGF:MonoUb-K,p-4Y-MET dimer:GRB2:p-Y-CBL,(HGF:MonoUb-K,p-Y1003,4Y-MET dimer:p-Y-CBL)
  - 'EPS15 '
  - HGF:p-Y,1349,Y1356-MET dimer
  - HGF:p-Y1234,Y1235,Y1349,Y1356-MET dimer
  - dimer:p-Y317-SHC1-2
  - RANBP9
  - PI(3,4,5)P3
  - 'Fibronectin matrix '
  - dimer:GRB2-1:SOS1
  - HGF dimer:MET
  - PTPN11
  - dimer:TNS4:ITGB1
  - HGF:p-4Y-MET:p-5Y-GAB1, HGF:p-4Y-MET:GRB2-1:p-5Y-GAB1:CRK,CRKL:(DOCK7)
  - RANBP10
  - 'Collagen fibres '
  - Integrin
  - HGF:p-4Y-MET:p-5Y-GAB1, HGF:p-4Y-MET:GRB2-1:p-5Y-GAB1:PTPN11
  - 'LRIG1 '
  - HGF:MonoUb-K,p-4Y-MET dimer:GRB2:p-Y-CBL,(HGF:MonoUb-K,p-Y1003,4Y-METdimer:p-Y-CBL):CIN85:endophillin:EPS15:HGS:STAM,(MET:Ub-LRIG1:EPS15:HGS:STAM)
  - 'p-Y1349,Y1356-MET '
  - HGF:MonoUb-K,p-4Y-MET dimer:GRB2:p-Y-CBL,(HGF:MonoUb-K,p-Y1003,4Y-METdimer:p-Y-CBL):CIN85:endophillin,(MET:Ub-LRIG1)
  - p21 RAS:GDP
  - 'CRKL '
  - HGFAC dimer
  - 'RAP1B '
  - 'MonoUb-K,p-Y1234,Y1235,Y1349,Y1356-MET '
  - 'ITGB1 '
  - 'HPN(163-417) '
  - 'PTPN11 '
  - 'p-Y194,Y397-PTK2 '
  - USP8
  - 'HGF(495-728) '
  - 'S-Farn-Me-2xPalmS HRAS '
  - SHC1-2
  - ADP
  - 'S-Farn-Me-PalmS KRAS4A '
  - GRB2-1
  - RAC1:GTP
  - 'PIK3CA '
  - dimer:p-Y397-PTK2
  - STAT3
  - H2O
  - HGF:p-4Y-MET:p-5Y-GAB1, HGF:p-4Y-MET:GRB2-1:p-5Y-GAB1:CRK,CRKL
  - 'p-Y194,Y397,Y576,Y577-PTK2 '
  - 'STAM2 '
  - 'RAC1 '
  - 'SOS1 '
  - 'Laminins '
  - TNS3
  - GGA3
  - HGF:p-4Y MET
  - PTPRJ
  - 'SH3KBP1 '
  - RAF/MAP kinase
  - 'DOCK7 '
  - 'ITGA2 '
  - 'UBC(609-684) '
  - GDP
  - HGF dimer
  - 'GTP '
  - 'ITGA3(33-1051) '
  - 'S-Farn-Me KRAS4B '
  - HPN heterodimer
  - unknown ubiquitin
  - 'SH3GL1 '
  - 'GGC-RAB4A '
  - 'GGA3 '
  - signaling
  - 'UBC(457-532) '
  - 'RAP1A '
  - 'GDP '
  - RAC1:GDP
  - Ub
  - 'Ub-LRIG1 '
  - 'GAB1 '
  - 'UBC(77-152) '
  - 'PIK3R1 '
  - 'HGF(32-494) '
  - (DOCK7)
  - dimer:GAB1
  - PIP3 activates AKT
  - 'p-Y705-STAT3 '
  - dimer:RANBP10
  - 'SH3GL3 '
  - 'RPS27A(1-76) '
  - 'UBC(533-608) '
  - CIN85:endophilin
  - 'p-Y397-PTK2 '
  - 'TNS4 '
  - alpha2beta1,alpha3:beta1:(collagen,laminin,fibronectin)
  - ATP
  - dimer:p-Y194,Y397-PTK2:MyrG-p-Y419-SRC
  - 'SH3GL2 '
  - 'PTK2 '
  - dimer:TNS3
  - dimer:GRB2-1:GAB1
  - dimer:p-Y317-SHC1-2:GRB2:SOS1
  - HGF:MET dimer
  - SPINT1,2
  - CBL:GRB2,CBL
  - 'SPINT2 '
  - GGC-RAB4:GTP
  - 'RANBP9 '
  - 'UBC(229-304) '
  - 'STAT3 '
  - Pi
  - GAB1
  - 'MonoUb-K,p-Y1003,4Y-MET '
  - dimer:PTK2
  - EPS15:HGS:STAM
  - PI(4,5)P2
  - 'p-Y-CBL '
  - HGF:MonoUb-K,p-4Y-MET dimer:GRB2:p-Y-CBL,(HGF:MonoUb-K,p-Y1003,4Y-METdimer:p-Y-CBL):CIN85:endophillin
  - HGF:p-Y1234,Y1235,Y1356-MET dimer
  - LRIG1
  - PTK2
  - MET:Ub-LRIG1
  - PIK3CA:PIK3R1
  - PTPN1,PTPN2
  - MUC20
  - 'p-5Y-GAB1 '
  - 'GGC-RAB4B '
  - RAP1:GTP
  - SPINT1
  - 'S-Farn-Me PalmS NRAS '
  - 'HPN(1-162) '
  - dimer,(HGF:p-Y1003,4Y-METdimer)
  - p-Y705-STAT3 dimer
  - 'p-Y317-SHC1-2 '
  - GRB2-1:SOS1
  - RAPGEF1
  - dimer:GRB2:CBL,(HGF:p-Y1003,4Y-MET dimer:CBL)
  - dimer:RANBP9:SOS1
  - 'GRB2-1 '
  - HGF:p-4Y-MET:p-5Y-GAB1, HGF:p-4Y-MET:GRB2-1:p-5Y-GAB1:CRK,CRKL:GGA3:ARF6:GTP
  - dimer:GRB2:p-Y-CBL,(HGF:p-Y1003,4Y-MET dimer:p-Y-CBL)
  - HGF:p-4Y-MET
  - RAP1:GDP
  - dimer:p-Y397-PTK2:MyrG-p-Y419-SRC
  - 'UBC(153-228) '
  - 'UBC(305-380) '
  - dimer:GAB1,HGF:p-4Y-MET dimer:GRB2:GAB1
  - 'RAPGEF1 '
  - HGF:p-4Y-MET:p-5Y-GAB1, HGF:p-4Y-MET:GRB2-1:p-5Y-GAB1:CRK,CRKL:RAPGEF1
  - 'UBB(1-76) '
  - 'UBB(153-228) '
  - 'HGFAC(373-407) '
  - 'RANBP10 '
  - 'SPINT1 '
  - dimer:MUC20
  - CRK, CRKL
  - MET:LRIG1
  - 'ARF6 '
  - MET
  - p-Y705-STAT3
  license: CC0
  name: Signaling by MET
seo: CreativeWork
title: Signaling by MET
wpid: WP4120
---